2023
A Phase 1b First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Crawford J, Calle R, Collins S, Weng Y, Lubaczewski S, Buckeridge C, Wang E, Harrington M, Tarachandani A, Rossulek M, Revkin J. A Phase 1b First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia. Clinical Cancer Research 2023, 30: 489-497. PMID: 37982848, PMCID: PMC10831332, DOI: 10.1158/1078-0432.ccr-23-1631.Peer-Reviewed Original ResearchThe mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review.
Dunne R, Bonomi P, Crawford J, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. The mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review. Journal Of Clinical Oncology 2023, 41: 87-87. DOI: 10.1200/jco.2023.41.4_suppl.87.Peer-Reviewed Original ResearchPancreatic cancerPoor survivalInternational Consensus Diagnostic CriteriaRisk of cachexiaUnintentional weight lossCancer-associated cachexiaSystematic literature reviewConsensus diagnostic criteriaProgressive functional impairmentPoor prognosisColorectal cancerUnivariate analysisMortality burdenFunctional impairmentCachexiaPRISMA guidelinesDiagnostic criteriaEligibility criteriaPatientsClinical practiceRoutine assessmentMultivariate analysisSignificant associationWasting disorderCancer
2022
1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review
Bonomi P, Crawford J, Dunne R, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. 1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review. Annals Of Oncology 2022, 33: s1281. DOI: 10.1016/j.annonc.2022.07.1919.Peer-Reviewed Original Research1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy
Roeland E, Fintelmann F, Yang R, Tarasenko L, McRae T, Revkin J, Bonomi P. 1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy. Annals Of Oncology 2022, 33: s1125. DOI: 10.1016/j.annonc.2022.07.1396.Peer-Reviewed Original Research